Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Davis LB, Sengul I, Ivy JS, Brock LGIII, Miles L. Scheduling food bank collections and deliveries to ensure food safety and improve access. Socioecon Plann Sci. 2014 Sep;48(3):175-88. doi: 10.1016/j.seps.2014.04.001
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Mines D. The ED status board as a threat to patient confidentiality. Ann Emerg Med. 1995 Jun;25(6):855-6.
Tanus T, Mines D, Atkins PC, Levinson AI. Serum tryptase in idiopathic anaphylaxis: a case report and review of the literature. Ann Emerg Med. 1994 Jul;24(1):104-7.
Mines D, Abbuhl S. Needle thoracostomy fails to detect a fatal tension pneumothorax. Ann Emerg Med. 1993 May;22(5):863-6.